Medindia

X

Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers

by Kathy Jones on  June 27, 2011 at 8:02 PM Drug News   - G J E 4
A two-year study on the new diabetes pill being developed by Bristol-Meyers and AstraZeneca was found to increase the risk of breast and bladder cancers though the drug was effective.
 Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers
Diabetes Drug Dapagliflozin Increases Risk of Breast and Bladder Cancers
Advertisement

According to AstraZeneca's Elisabeth Bjork, around 1.4 percent of those who were taking the drug, known as dapagliflozin, developed some form of cancer compared to 1.3 percent of those who did not take the drug during the study.

Advertisement
Analysts have pegged the annual sales of dapagliflozin to be over $631 million by 2015 but rejection of the drug by the Food and Drug Administration could cut the earnings of the companies by 3 to 6 percent.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All